Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and ...

Next, we assessed antigen binding of the modified Trastuzumab– 1c using biolayer interferometry (BLI) and confirmed that the introduction of a single lysine modification within the light chain of the ...